September/October 2021 NCI Cohort Consortium Member Newsletter

The 2021 NCI Cohort Consortium Virtual Annual Meeting - November 15-16, 2021

Register Now for the Annual Meeting

Registration is now open for the 2021 NCI Cohort Consortium Annual Meeting, which will be held virtually on November 15-16, 2021. Make sure to register by November 8, 2021.

For more information on the agenda, project group meetings, and speaker bios, visit the Annual Meeting website.

Project Group Meetings

Project group meetings are occurring between September 15-October 28. You can select which project groups you are interested in attending when you register for the Annual Meeting, and project group leaders will follow up with meeting information.

Cancer in Sexual and Gender Minorities Interest Group

A new interest group recently opened that focuses on cancer-related outcomes in sexual and gender minorities. They will be having their kick-off meeting on Tuesday, October 12th at 12pm. All are encouraged to attend. You can contact Dr. Sarah Jackson ( for more information.

Two Upcoming Cohort Consortium Webinars

Two Cohort Consortium webinars are now on the calendar!

  • October 20, 2021, 1:00pm - 2:00pm ET: Please join us to learn more about Measurements of Aging to Use in Cancer Cohort Studies. Frailty measures and aging trajectory data will be presented from the Women’s Health Initiative and other cohorts, and use of non-cancer comparison groups will be discussed. Register at
  • SAVE THE DATE November 5, 2021, 3:00pm - 4:00pm ET: The Associate Member Council will be holding a webinar for their members. The theme of this webinar is Getting Started with the NCI Cohort Consortium, and participants will be able to join in the discussion by selecting breakout room topics when they register.

Transdisciplinary Conference for Future Leaders in Precision Public Health - October 14-15, 2021

The Transdisciplinary Conference for Future Leaders in Precision Public HealthExternal Web Site Policy is a virtual event connecting future research leaders around the world interested in the role of genetics and precision health in the promotion of public health. This two-day conference will offer opportunities for early career investigators to discuss new developments in precision public health with leading experts in the field. Attendees will hear from expert epidemiologists, behavioral scientists, statisticians, and global public health leaders about topics such as health equity in genetic epidemiology, genetic risk communication in cancer care, and biostatistics and modeling.

Please registerExternal Web Site Policy by Friday, October 1, 2021.

SeroNet Adds Study Design Template for Booster Studies and Common Data Elements for COVID-19

SeroNet investigators collaboratively create study design templates and other guidance documents with the goal of encouraging harmonization across studies to allow for comparisons and meta-analyses.

A new design template and the COVID common data elements have been added to

The Study Design Template for Booster Studies includes recommendations for timepoints and assay types to study vaccine boosters. This template is intended to be tailored based on the study aims with the intent to collect samples at the same timepoints with the same associated metadata.

The COVID Common Data Elements is a work-in-progress that contains person focused, COVID vaccine, and disease/condition CDEs.

New Cohort Consortium Member

We welcome the England & Wales Hodgkin Lymphoma Cohort to the Consortium. You can contact Dr. Anthony Swerdlow ( or Dr. Aislinn Macklin-Doherty ( for more information about this cohort.

Recent Publications?

We would love to know about any Cohort Consortium-related publications that have come out recently! You can either add this information to the Cohort Consortium Project Hub or email us directly at

Funding Opportunity Announcements (FOAs) & Requests for Information (RFIs)

Funding Opportunity Announcements (FOAs)

  • Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01, Clinical Trial Optional)
  • Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01, Clinical Trial Optional)
  • Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research
    • Research Grants (U01, Clinical Trial Optional)
    • Coordinating Center (U24, Clinical Trial Not Allowed)
      Note: A pre-application webinar was held on August 11, 2021 (NOT-CA-21-094).
  • A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U01, Clinical Trial Not Allowed)
  • Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U24, Clinical Trial Not Allowed)
  • NCI Small Business Innovation Research Development Center (SBIR) Program Solicitation PHS 2022-1
  • Administrative Supplements to Promote Diversity in Small Business – SBIR/STTR (Admin Supp, Clinical Trial Not Allowed)
  • Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01, Clinical Trial Not Allowed)
  • Cancer Research Education Grants Program
    • Courses for Skills Development (R25, Clinical Trial Not Allowed)
    • Research Experiences (R25, Clinical Trial Not Allowed)
  • NCI Mentored Research Scientist Development Award to Promote Diversity (K01, Independent Clinical Trial Not Allowed, K01, Clinical Trial Required)
  • NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08, Clinical Trial Required; K08, Independent Clinical Trial Not Allowed)
  • NCI Transition Career Development Award to Promote Diversity (K22, Clinical Trial Required)
  • Emerging Global Leader Award (K43, Independent Clinical Trial Required; K43, Independent Clinical Trial Not Allowed)
  • NCI Outstanding Investigator Award (R35, Clinical Trial Not Allowed)
  • Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01, Clinical Trial Optional)
  • Limited Competition: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24, Clinical Trial Not Allowed)
  • The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01, Clinical Trial Optional)

Requests for Information (RFIs)

  • Systematic Review Centers with Nutrition Expertise for DRI Development (NOT-OD-21-173, responses due October 15, 2021)
  • Research Opportunities to End Hunger, Food and Nutrition Insecurity (NOT-OD-21-183, responses due November 1, 2021)

Upcoming Events